[Pharmacokinetic and clinical studies of SY5555 in the pediatric field. Pediatric Study Group of SY5555]. 1994

R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
Department of Pediatrics, School of Medicine, Teikyo University.

SY5555, a new oral penem, was pharmacokinetically and clinically evaluated in the pediatric field and the following results were obtained: 1. Pharmacokinetics Pharmacokinetics of SY5555 dry syrup (powder which is dissolved before use) was investigated in 64 children. At a dose level of 3 mg (potency)/kg, Cmax and T1/2 were 0.33 micrograms/ml and 0.95 hours (n = 1), respectively, in the non-fasting state. At a dose level of 5 mg/kg Cmax and T1/2 were 2.09 +/- 1.25 micrograms/ml and 1.20 +/- 1.07 hours, respectively, in the fasting state, and were 1.21 +/- 0.70 micrograms/ml and 1.33 +/- 0.90 hours, respectively, in the non-fasting state. At a dose level of 10 mg/kg, Cmax and T1/2 were 2.96 +/- 1.89 micrograms/ml and 0.89 +/- 0.43 hours, respectively, in the fasting state, and were 2.45 +/- 1.37 micrograms/ml and 1.17 +/- 0.53 hours, respectively, in the non-fasting state. At a dose level of 15 mg/kg, Cmax and T1/2 were 4.30 +/- 2.15 micrograms/ml and 0.82 +/- 0.09 hours, respectively, in the non-fasting state. Data of Cmax and AUC showed that plasma concentration of the drug depended on dose levels. Urinary recovery rates in the first 6 hours were 1.71% (n = 1) in the non-fasting state at a dose level of 3 mg/kg, 4.13 +/- 1.40% in the fasting state and 4.17 +/- 3.29% in the fasting and the non-fasting state, respectively at a dose level of 5 mg/kg, and 6.02% (n = 1) and 4.64 +/- 2.81%, respectively, at a dose level of 10 mg/kg. At a dose level of 15 mg/kg, urinary recovery rate in the first 6 hours was 7.97% (n = 2) in the non-fasting state. 2. Clinical results 1) Dry syrup The clinical efficacy of the SY5555 dry syrup was evaluated in 506 cases. SY5555 was administered at daily doses of 15-30 mg/kg divided into 3 equal doses to most patients. Daily doses of 12- < 18 mg/kg were given to 46.6% of the patients. The overall clinical efficacy rate was 92.9%, and this drug was effective in 93.0% of the 301 patients for whom the causative pathogens were identified, and in 92.7% of the 205 patients with infections for whom the causative pathogens were unknown. The efficacy rate at daily doses of 12 - < 18 mg/kg was 94.5% similar to those obtained at daily doses of 18- < 27 mg/kg (91.7%) or 27- < 33 mg/kg (91.3%). The bacteriological eradication rate was 82.3%.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.

Related Publications

R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
February 1995, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
January 1995, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
February 1995, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
February 1995, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
October 1991, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
June 1992, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
January 1993, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
November 1985, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
January 1995, The Japanese journal of antibiotics,
R Fujii, and T Abe, and T Tajima, and I Terashima, and H Meguro, and H Sato, and K Niino, and H Suzuki, and Y Toyonaga, and H Nakamura
September 1995, The Japanese journal of antibiotics,
Copied contents to your clipboard!